Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.52 |
| ▸ | ADH1A | P07327 | 4/20 | 0.52 |
| ▸ | ADH1C | P00326 | 3/20 | 0.52 |
| ▸ | ADH7 | P40394 | 2/20 | 0.52 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 15/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771083 | 0.88 | — | — | |
| SCHEMBL359530 | 0.88 | — | — | |
| SCHEMBL799528 | 0.88 | — | — | |
| SCHEMBL14231203 | 0.84 | ADH1B (0.58) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL21362335 | 0.80 | KAT2B (0.37) | KAT2BBPTF | |
| SCHEMBL3756245 | 0.78 | — | — | |
| SCHEMBL19575583 | 0.77 | ALDH1A1 (0.48) | KAT2BBPTF | |
| SCHEMBL27630196 | 0.77 | ALDH1A1 (0.42) | KAT2BBPTF | |
| SCHEMBL27630195 | 0.77 | ALDH1A1 (0.42) | KAT2BBPTF | |
| SCHEMBL3926638 | 0.76 | ADH1B (0.47) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133271-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-07-13 | — | — | WO | disclosed |
| EP-3992191-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | Deutsches Krebsforschungszentrum (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| CN-109715612-A | SOMATOSTATIN MODULATORS AND USES THEREOF | 克林提克斯医药股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-104072489-B | Therapeutic isoxazole compounds | 达特神经科学(开曼)有限公司 | 2017-07-07 | — | — | CN | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| WO-2009007390-A2 | 2-PYRAZ INYLBENZ IMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | ADH1B 3574/4885ADH1A 1281/4885ADH1C 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.